Neurophenotypes of COVID-19: risk factors and recovery outcomes.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
pubmed:
5
1
2023
medline:
5
1
2023
entrez:
4
1
2023
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) infection is associated with risk of persistent neurocognitive and neuropsychiatric complications, termed "long COVID". It is unclear whether the neuropsychological manifestations of COVID-19 present as a uniform syndrome or as distinct neurophenotypes with differing risk factors and recovery outcomes. We examined post-acute neuropsychological profiles following SARS-CoV-2 infection in 205 patients recruited from inpatient and outpatient populations, using an unsupervised machine learning cluster analysis, with objective and subjective measures as input features. This resulted in three distinct post-COVID clusters. In the largest cluster (69%), cognitive functions were within normal limits, although mild subjective attention and memory complaints were reported. Vaccination was associated with membership in this "normal cognition" phenotype. Cognitive impairment was present in the remaining 31% of the sample but clustered into two differentially impaired groups. In 16% of participants, memory deficits, slowed processing speed, and fatigue were predominant. Risk factors for membership in the "memory-speed impaired" neurophenotype included anosmia and more severe COVID-19 infection. In the remaining 15% of participants, executive dysfunction was predominant. Risk factors for membership in this milder "dysexecutive" neurophenotype included disease-nonspecific factors such as neighborhood deprivation and obesity. Recovery outcomes at 6-month follow-up differed across neurophenotypes, with the normal cognition group showing improvement in verbal memory and psychomotor speed, the dysexecutive group showing improvement in cognitive flexibility, and the memory-speed impaired group showing no objective improvement and relatively worse functional outcomes compared to the other two clusters. These results indicate that there are multiple post-acute neurophenotypes of long COVID, with different etiological pathways and recovery outcomes. This information may inform phenotype-specific approaches to treatment.
Identifiants
pubmed: 36597538
doi: 10.21203/rs.3.rs-2363210/v2
pmc: PMC9810229
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIA NIH HHS
ID : K23 AG064029
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG057195
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG032438
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Eur J Neurol. 2021 Oct;28(10):3324-3331
pubmed: 33369818
Ann Clin Transl Neurol. 2021 May;8(5):1073-1085
pubmed: 33755344
Nature. 2022 Apr;604(7907):697-707
pubmed: 35255491
Pain Res Treat. 2016;2016:7217684
pubmed: 27242925
N Engl J Med. 2013 Oct 3;369(14):1306-16
pubmed: 24088092
J Patient Rep Outcomes. 2022 Jun 23;6(1):72
pubmed: 35737279
Lancet Psychiatry. 2022 Oct;9(10):815-827
pubmed: 35987197
Arch Phys Med Rehabil. 2021 Jan;102(1):115-131
pubmed: 32339483
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Brain Inj. 2020 Feb 23;34(3):369-374
pubmed: 32026729
J Neurol. 2022 Aug;269(8):3982-3989
pubmed: 35325308
Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2200960119
pubmed: 35951647
Mayo Clin Proc Innov Qual Outcomes. 2021 Nov 10;5(6):1056-1065
pubmed: 34820597
Brain Commun. 2022 Jan 19;4(1):fcab295
pubmed: 35128398
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Med Care. 2009 Jun;47(6):626-33
pubmed: 19433995
Brain Behav Immun Health. 2023 Feb;27:100587
pubmed: 36624888
Cortex. 2022 Sep;154:212-230
pubmed: 35780756
World Med Health Policy. 2020 Dec;12(4):344-346
pubmed: 33362940
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Clin Trials. 2020 Oct;17(5):472-482
pubmed: 32674594
J Gen Intern Med. 2007 Sep;22(9):1321-4
pubmed: 17634781
Nat Commun. 2022 Oct 12;13(1):5663
pubmed: 36224173
Epidemiol Rev. 2007;29:6-28
pubmed: 17510091
Crit Care. 2022 Jul 20;26(1):223
pubmed: 35858899
Nat Neurosci. 2021 Feb;24(2):168-175
pubmed: 33257876
Nat Immunol. 2022 Feb;23(2):194-202
pubmed: 35105985
Brain Behav Immun. 2022 Mar;101:93-135
pubmed: 34973396
N Engl J Med. 2018 Jun 28;378(26):2456-2458
pubmed: 29949490
Psychiatr Serv. 2021 May 1;72(5):598-601
pubmed: 33593101
Sci Transl Med. 2021 Jul 14;13(602):
pubmed: 34131052
J R Soc Med. 2020 Oct;113(10):394-402
pubmed: 32930040
JAMA Netw Open. 2021 Oct 1;4(10):e2130645
pubmed: 34677597
J Neurol Sci. 2022 Jul 15;438:120146
pubmed: 35031121
Curr Opin Neurol. 2022 Apr 1;35(2):212-219
pubmed: 35102125
Eur J Pharmacol. 2008 May 6;585(1):97-108
pubmed: 18395201
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Brain Behav Immun Health. 2020 Dec;9:100163
pubmed: 33111132
Neurologia. 2022 Aug 3;:
pubmed: 35936979
Chronic Illn. 2022 Sep;18(3):691-701
pubmed: 35821571
Clin Neuropsychol. 2020 Apr;34(3):437-453
pubmed: 32037942
Brain. 2021 Oct 22;144(9):2696-2708
pubmed: 33856027
Arch Clin Neuropsychol. 2006 Oct;21(7):623-43
pubmed: 17014981
Lancet Respir Med. 2020 Jul;8(7):659-661
pubmed: 32437646
Clin Infect Dis. 2021 Nov 2;73(9):e3019-e3026
pubmed: 33395482
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Nat Rev Immunol. 2021 Nov;21(11):694-703
pubmed: 34373622
MedGenMed. 2007 Oct 03;9(4):3
pubmed: 18311353
Lancet Respir Med. 2021 Nov;9(11):1275-1287
pubmed: 34627560